alpha linkage between the first protected saccharide and the second protected saccharide,

wherein the first protected saccharide is selected from the group consisting of a D-glucosamine unit and an oligosaccharide comprised of alternating D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal D-glucosamine at the reducing end, and

wherein the second protected saccharide is selected from the group consisting of a uronic acid unit and an oligosaccharide comprised of alternating D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal uronic acid at the non-reducing end, further

wherein any uronic acid unit is selected from the group consisting of D-glucuronic acid and L-iduronic acid and further

wherein any D-glucosamine units have nitrogen containing groups at carbon 2, which nitrogen containing groups can be treated to form an amine.

2

condensation product having from 2 - 12 saccharide units and having semi-permanent protecting groups and permanent protecting groups as substituents at carbon positions thereon to allow selective positioning of functional groups at desired positions, and further having other protecting groups which form an ester at carboxyl groups, and having nitrogen containing groups as substituents at position 2 of D-glucosamine units, which process

comprises the step of condensing a first protected saccharide with a second protected saccharide to form a protected condensation product,

wherein the first protected saccharide is selected from the group consisting of a protected D-glucosamine unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal D-glucosamine at the reducing end, further wherein the first protected saccharide has a reactive group as a substituent at carbon 1 at the reducing end which reactive group allows a stereospecific linkage during the condensation, and

wherein the second protected saccharide is selected from the group consisting of a protected uronic acid unit and an oligo-saccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal uronic acid at the nonreducing end, wherein any uronic acid units are selected from the group consisting of D-glucuronic acid and L-iduronic acid, and

wherein the protected condensation product formed has a 1-4 alpha linkage between the first protected saccharide and the second protected saccharide, the protected condensation product further having at least one each of semi-permanent protecting groups, permanent protecting groups, other protecting groups, and nitrogen containing groups as substituents at carbon positions thereon which protecting groups and nitrogen containing groups were present on the first protected saccharide and second protect-

ed saccharide, which semi-permanent protecting groups are removable in the presence of permanent protecting groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, which permanent protecting groups are stable and do not migrate to different carbon positions during the removal of the semi-permanent protecting groups and the introduction of functional groups to replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of -0-SO3 groups and -0-PO3 groups, and which permanent protecting groups also are removable in the presence of the functional groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, and which other protecting groups form an ester at the carboxyl group of the uronic acid units and are stable during the condensation, and which nitrogen containing groups are substituents at carbon 2 of the D-glucosamine units, can be treated to form an amine, are stable during the condensation, and allow a stereospecific linkage during the condensation.

condensation product having from 2 - 12 saccharide units and having semi-permanent protecting groups and permanent protecting groups as substituents at carbon positions thereon to allow selective positioning of functional groups at desired positions, further having other protecting groups which form an ester at the carboxyl groups, and nitrogen containing groups as substituents

at carbon positions thereon, which process comprises condensing a first protected saccharide with a second protected saccharide to form a protected condensation product

wherein the first protected saccharide is selected from the group consisting of a protected uronic acid unit and an oligosaccharide comprised of alternating D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal uronic acid at the reducing end, further wherein the first protected saccharide has a reactive group as a substituent at carbon 1 at the reducing end which reactive group allows the condensation to occur and which allows a stereospecific linkage during the condensation, and

wherein the second protected saccharide is selected from the group consisting of a protected D-glucosamine unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal D-glucosamine at the nonreducing end, wherein any uronic acid units are selected from the group consisting of D-glucuronic acid and L-iduronic acid, and wherein the protected condensation product formed has a 1-4 beta linkage between the first protected saccharide and the second protected saccharide where the first protected saccharide is a D-glucuronic acid or an oligosaccharide having a terminal D-glucuronic acid, and wherein the protected condensation product formed has a 1-4 alpha linkage between the first protected saccharide and the second protected saccharide where the first protected saccharide is an L-iduronic

acid or an oligosaccharide having a terminal L-iduronic acid, the protected condensation product further having at least one each of semi-permanent protecting groups, permanent protecting groups, other protecting groups, and nitrogen containing groups as substituents at carbon positions thereon which protecting groups and nitrogen containing groups were present on the first protected saccharide and second protected saccharide, which semi-permanent protecting groups are removable in the presence of permanent protecting groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, which permanent protecting groups are stable and do not migrate to different carbon positions during the removal of semi-permanent protecting groups and the introduction of functional groups to replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of -0-SO3 groups and -0-PO3 groups, and which permanent protecting groups also are removable in the presence of the functional groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, and which other protecting groups form an ester at the carboxyl groups of the uronic acid units, and are stable during the condensation, and which nitrogen containing groups comprise nitrogen containing groups at carbon 2 of the D-glucosamine units, which nitrogen containing groups can be treated to form an amine, are stable during the condensation, and allow a stereospecific linkage during the condensation.

I

condensation product having from 2 - 12 saccharide units and having semi-permanent protecting groups and permanent protecting groups as substituents at carbon positions thereon to allow selective positioning of functional groups at desired positions, further having other protecting groups which form an ester at the carboxyl groups and further having nitrogen containing groups at position 2 of D-glucosamine units which process comprises a first step of condensing a first protected saccharide with a second protected saccharide precursor to form a protected condensation product

wherein the first protected saccharide is selected from the group consisting of a protected uronic acid unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal uronic acid at the reducing end, further wherein the first protected saccharide has a reactive group as a substituent at carbon 1 at the reducing end which reactive group allows a stereospecific linkage during the condensation, and

wherein the second protected saccharide is a glucose derivative which is a D-glucosamine precursor, which D-glucosamine precursor has one or more precursor groups as substituents which are selected from the group consisting of a 1, 6 anhydro group and a 2, 3 epoxy group, further wherein any uronic acid units are selected from the group consisting of D-glucuronic acid and L-iduronic acid, and

wherein the protected condensation product formed has a 1-4 beta linkage between the first protected saccharide and the second protected saccharide where the first protected saccharide is a D-glucuronic acid or an oligosaccharide having a terminal D-glucuronic acid, and wherein the protected condensation product formed has a 1-4 alpha linkage between the first protected saccharide and the second protected saccharide where the first protected saccharide is an L-iduronic acid or an oligosaccharide having a terminal L-iduronic acid, the protected condensation product further having protecting groups and precursor groups as substituents at carbon positions thereon, which protecting groups and precursor groups were present on the first and second protected saccharide,

further comprising the second step of treating any 1,6 anhydro precursor group to form semi-permanent protecting groups or permanent protecting groups at carbons 1 and 6 and treating any 2, 3 epoxy precursor group to form a semi-permanent protecting group or a permanent protecting group at carbon 3 and a nitrogen containing group at carbon 2, which semi-permanent protecting groups are removable in the presence of permanent protecting groups, and which permanent protecting groups are stable and do not migrate to different carbon positions during the removal of semi-permanent protecting groups and the introduction of functional groups to replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of -O-SO₃ groups and -O-PO₃ groups, and which permanent protecting

1

groups also are removable in the presence of the functional groups, and which other protecting groups form an ester at the carboxyl groups of the uronic acid units and are stable during the condensation, and which nitrogen containing groups occupy carbon 2 of the D-glucosamine units, can be treated to form an amine, are stable during the condensation and allow a stereospecific linkage during the condensation.

A process as in claim 142, 143 or 144 wherein the functional groups are -0-SO₃ groups.

A process as in claim 165 wherein the semi-permanent protecting groups are substituents at one or more carbon positions at any of carbons 3 and 6 of D-glucosamine units, and carbons 2 and 3 of uronic acid units, and wherein the permanent protecting groups are substituents at the carbons 3 and 6 of the D-glucosamine units and carbons 2 and 3 of the uronic acid units which are not occupied by the semi-permanent protecting groups.

13. The process of claim 146 wherein

- a) The nitrogen containing groups are selected from the group consisting of
 - 1. N_3 ,
 - 2. NH lower acyl, and
 - 3. NHCO lower arylalkyl;

- b) the protecting groups which form an ester at the carboxyl are selected from the group consisting of
 - 1. lower alkyl, and
 - 2. lower aryl;
- c) the semi-permanent protecting groups are -O-lower acyl;
- d) the permanent protecting groups are -0-benzyl; and
- e) the reactive group is selected from the group consisting of
 - 1. halogen,
 - 2. 0-lower imidoyl, and
 - 3. Lan orthoester formed between carbon 1 and carbon 2 of D-glucosamine.

148. The process of claim 149 wherein

- a) The nitrogen containing groups are selected from the group consisting of
 - 1. N_3 ,
 - 2. NH acetyl, and
 - 3. NHCO benzyl;
- b) the protecting groups which forms an ester at the carboxyl are methyl;
- c) the semi-permanent groups are -0-acetyl;
 - d) the permanent protecting groups are -O-benzyl; and
 - e) the reactive group is selected from the group consisting of

- 1. Br,
- 2. Cl,
- 3. an orthoester having between 3 and 6 carbons, and
- 4. C(NH) CC1₃.

A process according to claim 144 wherein the second protected saccharide is a glucose derivative which is a D-glucosamine precursor which contains a 1, 6 anhydro group, wherein the 1, 6 anhydro group is treated with an acetolysing agent to obtain -O-acetyl semi-permanent protecting groups.

Jacoba A process according to claim 109 wherein the D-glucosamine precursor also contains a 2, 3 epoxide group, wherein the 2, 3 epoxide group is opened with a nucleophile and the resulting OH is acetylated at the position 3 carbon to obtain an -0-acetyl semi-permanent protecting group at carbon 3 and an azide nitrogen containing group at carbon 2.

A process according to claim 149 wherein the D-glucosamine precursor also contains a 2, 3 epoxide group, wherein the 2, 3 epoxide group is opened with a nucleophile and the resulting OH is benzylated at the position 3 carbon to obtain an -O-benzyl permanent protecting group at carbon 3 and an azide nitrogen containing group at carbon 2.

152. A process according to claim 150 or 151 wherein the nucleophile is sodium azide and the nitrogen containing group is $N_3.$

A process according to claim 14 wherein the D-glucosamine unit contains a 1,6 anhydro group, comprising treating with an acetolysing agent in order to obtain an -O-acetyl group at carbon 1 of the D-glucosamine, further comprising the step of removing the acetyl group and replacing it with a reactive group in order to allow the protected condensation product to be elongated.

A process according to claim 153 wherein the reactive group is selected from the group consisting of bromine and chlorine.

at the reducing end of the protected condensation product is occupied by a protecting group which is selected from the group consisting of a semi-permanent protecting group and a permanent protecting group.

156. A process as in claim 122 or 143 wherein the carbon 4 at the non-reducing end of the protected condensation product is occupied by a protecting group which is selected from the group

consisting of a semi-permanent protecting group and a permanent protecting group.

A process as in claim 142 or 143 further wherein the carbon 1 at the reducing end of the protected condensation product is occupied by an inert protecting group, which inert protecting group is stable during the condensation and during removal of the permanent protecting groups.

condensation product which can be elongated, having from 2 - 12 saccharide units and having semi-permanent protecting groups and permanent protecting groups as substituents at carbon positions thereon to allow selective positioning of functional groups at desired positions, and further having other protecting groups which form an ester at carboxyl groups, and having nitrogen containing groups as substituents at position 2 of D-glucosamine units, and further having temporary groups positioned thereon to allow elongation of the protected condensation product, which process comprises condensing a first protected saccharide with a second protected saccharide to form a protected condensation product

wherein the first protected saccharide is selected from the group consisting of a protected D-glucosamine unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and

having a terminal D-glucosamine at the reducing end, further wherein the first protected saccharide has a reactive group as a substituent at carbon 1 at the reducing end which reactive group allows the condensation to occur and also allows a stereospecific linkage during the condensation, and

wherein the second protected saccharide is selected from the group consisting of a protected uronic acid unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal uronic acid at the nonreducing end, wherein any uronic acid is selected from the group consisting of D-glucuronic acid and L-iduronic acid, and

wherein the protected condensation product has a 1-4 alpha linkage between the first protected saccharide and the second protected saccharide, the protected condensation product further having at least one each of semi-permanent protecting groups, permanent protecting groups, temporary protecting groups, other protecting groups, and nitrogen containing groups as substituents at carbon positions thereon which protecting groups and nitrogen containing groups were present on the first protected saccharide and second protected saccharide, which semi-permanent protecting groups are removable in the presence of permanent protecting groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, which permanent protecting groups are stable and do not migrate to different carbon positions during introduction of functional groups to

1

replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of -0-SO3 groups and -0-PO3 groups, and which permanent protecting groups also are removable in the presence of the functional groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, which other protecting groups form an ester at the carboxyl groups of the uronic acid units, and are stable during the condensation, which temporary protecting groups are substituents at any of carbon 1 at the reducing end of the protected condensation product and carbon 4 at the non-reducing end of the protected condensation product and are removable in the presence of the semi-permanent protecting groups and permanent protecting groups in order to permit elongation of the protected condensation product, and which nitrogen containing groups are substituents at carbon 2 of the D-glucosamine units, can be treated to form an amine, are stable during the condensation, and allow a stereospecific linkage during the condensation.

259. A process for synthesizing a protected heparinic condensation product which can be elongated, having from 2 - 12 saccharide units and having semi-permanent protecting groups and permanent protecting groups as substituents at carbon positions thereon to allow selective positioning of functional groups at desired positions, and further having other protecting groups which form an ester at carboxyl groups, and having nitrogen containing groups as substituents at position 2 of D-glucosamine

units, and further having temporary groups positioned thereon to allow elongation of the protected condensation product, which process comprises condensing a first protected saccharide with a second protected saccharide to form a protected condensation product

wherein the first protected saccharide is selected from the group consisting of a protected uronic acid unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal uronic acid at the reducing end, further wherein the first protected saccharide has a reactive group as a substituent at carbon 1 at the reducing end, which reactive group allows a stereospecific linkage during the condensation, and

wherein the second protected saccharide is selected from the group consisting of a protected D-glucosamine unit and an oligosaccharide comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having a terminal D-glucosamine at the nonreducing end, wherein any uronic acid is selected from the group consisting of D-glucuronic acid and L-iduronic acid, and

wherein the protected condensation product has a 1-4 beta linkage between the first protected saccharide and the second protected saccharide where the first protected saccharide is a D-glucuronic acid unit or an oligosaccharide having a terminal D-glucuronic acid, and a 1-4 alpha linkage between the first protected saccharide and the second protected saccharide where

1

the first protected saccharide is an L-iduronic acid unit or an oligosaccharide having a terminal L-iduronic acid, the protected condensation product further having at least one each of semipermanent protecting groups, permanent protecting groups, temporary protecting groups, other protecting groups, and nitrogen containing groups as substituents at carbon positions thereon which protecting groups and nitrogen containing groups were present on the first protected saccharide and second protected saccharide, which semi-permanent protecting groups are removable in the presence of permanent protecting groups, are stable during the condensation, and allow a stereospecific linkage during the condensation, which permanent protecting groups are stable and do not migrate to different carbon positions during introduction of functional groups to replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of -0-SO3 groups and -0-PO3 groups, and which permanent protecting groups also are removable in the presence of the functional groups, are stable during the condensation, allow a stereospecific linkage during the condensation, which other protecting groups form an ester at the carboxyl groups of the uronic acid units and are stable during the condensation, which temporary protecting groups are substituents at any of carbon 1 at the reducing end of the protected condensation product and carbon 4 at the nonreducing end of the protected condensation product, and are removable in the presence of the semi-permanent protecting groups and permanent protecting groups in order to permit elongation of

the protected condensation product, and which nitrogen containing groups are substituents at carbon 2 of the D-glucosamine units, can be treated to form an amine, are stable during the condensation, and allow a stereospecific linkage during the condensation.

160. A process as in claim 158 or 139 wherein the functional groups are -0-SO₃ groups.

161. A process as in claim 160 wherein the semi-permanent protecting groups are substituents at one or more carbon positions at any of carbons 3 and 6 of D-glucosamine units, and carbons 2 and 3 of uronic acid units, and wherein the permanent protecting groups are substituents at the carbons 3 and 6 of the D-glucosamine units and carbons 2 and 3 of the uronic acid units which are not occupied by the semi-permanent protecting groups.

162. A process according to claim 161 further comprising the steps of removing a temporary protecting group at carbon one at the reducing end of the protected condensation product, substituting a reactive group and performing a second condensation to form an elongated protected condensation product comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having protecting groups thereon.

163. A process according to claims 161 further comprising the steps of removing the temporary group at carbon 4 of the non-reducing end of the protected condensation product and performing a second condensation to form an elongated condensation product comprised of alternating protected D-glucosamine and uronic acid units linked in the manner found in heparin and having protecting groups thereon.

164.

The process of claim 151 wherein

- a) The nitrogen containing groups are selected from the group consisting of
 - 1. N₃,
 - 2. NH lower acyl, and
 - 3. NHCO lower arylalkyl;
- b) the protecting groups at the carboxyl are selected from the group consisting of
 - 1. lower alkyl, and
 - 2. lower aryl;
- c) the semi-permanent protecting groups are -O-lower acyl;
- d) the permanent protecting groups are -0-benzyl; and
- e) the reactive group is selected from the group consisting of
 - 1. halogen,
 - 2. -O-lower imidoyl, and

-19-

- an orthoester formed between carbon 1 and carbon 2 of D-glucosamine;
- f) the temporary group is selected from the group consisting of
 - 1. -O-lower acyl,
 - 2. -0-allyl,
 - -O-propenyl,
 - 4. halogenated -O-lower acyl, and
 - 5. -O-p-methoxy benzoyl.

185. The process of claim 164 wherein

- a) The nitrogen containing groups are selected from the group consisting of
 - 1. N_3 ,
 - 2. NH acetyl, and
 - 3. NHCO benzyl;
- b) The protecting groups which forms an ester at the carboxyl are methyl;
- c) The semi-permanent groups are -O-acetyl;
- d) The permanent protecting groups are -O-benzyl; and
- e) the reactive group is selected from the group consisting of
 - 1. Br,
 - 2. Cl,
 - an orthoester having between 3 and 6 carbons, and

- 4. C(NH)CC13;
- f) The temporary protecting groups are selected from the group consisting of
 - 1. -0-acetyl,
 - 2. -O-allyl,
 - 3. -O-propenyl,
 - 4. monochloro-O-acetyl,
 - 5. trichloro-O-acetyl, and
 - 6. -O-p-methoxy benzoyl.

or phosphate groups on a protected heparinic polysaccharide having from 2-12 units, which polysaccharide is comprised of alternating D-glucosamine and uronic acid units linked in the manner found in heparin and having at least one each as substituents of semipermanent protecting groups, permanent protecting groups other protecting groups which form an ester at the carboxyl groups of the uronic acid units, and nitrogen containing groups at carbon 2 of the D-glucosamine units, wherein the permanent protecting groups are stable and do not migrate to other carbon positions during removal of the semi-permanent protecting groups and the introduction of functional groups, and wherein any uronic acid units are selected from the group consisting of D-glucuronic acid and L-iduronic acid, which process comprises the steps of

a) removing the semi-permanent protecting groups,

1

- b) introducing functional groups in place of the semipermanent protecting groups, which functional groups are selected from the group consisting of -O-SO₃ groups and -O-PO₃ groups, and
- c) removing the permanent protecting groups and converting the nitrogen containing group into an amine group.

1

16/7. A process as in claim 166 wherein the functional groups are -0-SO3 groups.

36. A process as in claim wherein the semi-permanent protecting groups are substituents at one or more carbon positions at any of carbons 3 and 6 of D-glucosamine units, and carbons 2 and 3 of uronic acid units, and wherein the permanent protecting groups are substituents at the carbons 3 and 6 of the D-glucosamine units and carbons 2 and 3 of the uronic acid units which are not occupied by the semi-permanent protecting groups.

34

The process of claim 158 wherein

- a) The nitrogen containing groups are selected from the group consisting of
 - 1. N_3 ,
 - 2. NH lower acyl, and
 - NHCO lower arylalkyl;

- b) the protecting groups at the carboxyl are selected from the group consisting of
 - 1. lower alkyl, and
 - 2. lower aryl;
- c) the semi-permanent protecting groups are -0-lower acyl; and
- d) the permanent protecting groups are -O-benzyl.

35

170. The process of claim 189 wherein

- a) The nitrogen containing groups are selected from the group consisting of
 - 1. N_3 ,
 - 2. NH acetyl, and
 - 3. NHCO benzyl;
- b) The protecting groups which forms an ester at the carboxyl are methyl;
- c) The semi-permanent groups are -0-acetyl; and
- d) The permanent protecting groups are -O-benzyl.

of substituting the amine group with a group selected from the group consisting of SO₃ and acyl.

A process as in claim 171 wherein the amine group is substituted with a group selected from the group consisting of SO₃ and acetyl.

38 1/3. A process as in claim 1/2 further comprising removing the protecting groups at the carboxyl groups of the uronic acid units.

38 371. The process of claim 1/3 which further comprises salifying the COO with an alkaline metal cation.

The process of claim 186 wherein the semi-permanent protecting groups are acetyl and are hydrolysed with a strong base followed by reaction with a sulfation agent.

The process of claim 175 wherein following introduction of the functional group -0-SO₃ the compound formed is purified by fractionation.

The process of claim 176 wherein following fractionation of the compound, the compound is passed through a sodium ion exchange column.

The process of claim if wherein the condensation reaction is between a halide and an OH and is carried out in a solvent medium in the presence of a catalyst.

179. The process of claim 178 wherein the solvent is an organic solvent selected from the group consisting of dichloro-

methane and dichloroethane and the catalyst is selected from the group consisting of a silver and a mercury salt.

180. The process of claim 179 wherein the catalyst is selected from the group consisting of triflouromethane, silver carbonate, silver oxide, mercuric bromide and mercuric cyanide.

The process of claim 143 or 144 wherein the reactive group is 1,2-0-methoxyethylidene, and the condensation is carried out in a solvent which boils above 100 degrees centigrade in the presence of a catalyst.

The process of claim 18 wherein the reactive group is 0-lower imidoyl and the condensation reaction is carried out in the presence of a catalyst at a temperature below or equal to 0 degrees centigrade.


A process for selectively positioning sulfate groups or phosphate groups on a protected heparinic polysaccharide having from 2-12 units, which protected heparinic polysaccharide is comprised of alternating units of a first unit and a second unit wherein the first unit is selected from the group consisting of a D-glucosamine, a neutral sugar analog of D-glucosamine, and a desoxy sugar analog of D-glucosamine, and wherein the second unit is selected from the group consisting of a uronic acid, a neutral sugar analog of uronic acid, and a desoxy sugar analog of uronic


acid, further wherein any uronic acid is selected from the group consisting of D-glucuronic acid and L-iduronic acid, the first and second unit being linked in the manner found in heparin and having at least on each as substituents of semi-permanent protecting groups, permanent protecting groups, other protecting groups which form an ester at the carboxyl groups of the uronic acid units, and nitrogen containing groups at carbon 2 of the D-glucosamine units wherein the permanent protecting groups are stable and do not migrate to other carbon positions during removal of the semi-permanent protecting groups and the introduction of functional groups, which process comprises the steps of


- a) removing the semi-permanent protecting groups,
- b) introducing functional groups in place of the semipermanent protecting groups, which functional groups are selected from the group consisting of -0-SO₃ groups and -0-PO₃ groups, and
- c) removing the permanent protecting groups and converting the nitrogen containing group into an amine group.

44

184. A substantially pure compound of a single structure, which compound is selected from the group consisting of:







wherein

 R_1 substituents are not the same, and are selected from the group consisting of

- a) semi-permanent protecting groups which semipermanent protecting groups are removable in the
 presence of permanent protecting groups, are stable
 during any condensation employed to obtain the compound
 and allow a stereospecific linkage during the
 condensation, and are stable during removal of any
 temporary group,
- b) permanent protecting groups which permanent protecting groups are stable and do not migrate to different carbon positions during removal of the semipermanent protecting groups and the introduction of functional groups to replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of SO₃ groups and PO₃ groups, and which permanent protecting groups also are removable in the presence of the functional groups, are stable during the condensation, and which allow a stereospecific linkage during the condensation, and which permanent protecting groups are stable during removal of any temporary protecting group,

M is a protecting group which forms an ester at the carboxyl groups, and is stable during any condensation employed to obtain the compound,

1

N is a nitrogen containing group which may be treated to form an amine, and which allows a stereospecific linkage during any condensation employed to obtain the compound,

R is selected from the group consisting of:

a) a temporary protecting group which can be removed in the presence of the semi-permanent protecting groups and permanent protecting groups in order to

during any condensation employed to obtain the compound,

permit elongation of the compound and which is stable

b) a permanent protecting group,

c) a reactive group which can be employed in order to perform a condensation to form a 1-4 linkage as found in heparin in order to elongate the compound, and which reactive group was positioned following removal of a temporary protecting group and which allows a stereospecific linkage during the condensation,

d) an inert protecting group, which is stable during removal of the temporary protecting groups, semi-permanent protecting groups and permanent protecting groups, and

R' is selected from the group consisting of

- a) a temporary protecting group,
- b) a permanent protecting group, and
- c) an OH group.

The substantially pure compound of claim 184 wherein the compound can be elongated and R is selected from the group consisting of a temporary protecting group and a reactive group.

186. The substantially pure compound of claim 184 wherein the compound can be elongated and R' is selected from the group consisting of a temporary protecting group and OH.

187. A substantially pure compound of a single structure, which compound is selected from the group consisting of:

Compounds I, III, V, VI, VII, VIII, IX, X, XI and XII wherein

R₁ substituents are not the same, and are selected from the group consisting of

- a) OH groups, and
- b) permanent protecting groups, which permanent protecting groups are stable and do not migrate to different carbon positions during removal of the semipermanent protecting groups and the introduction of functional groups to replace the semi-permanent protecting groups, which functional groups are selected from the group consisting of SO₃ groups and PO₃ groups, which permanent protecting groups also are removable in the presence of the functional groups, are stable during the condensation, and which allow a stereospecific linkage during any condensation employed to obtain the

compound, and which permanent protecting groups are stable during removal of any temporary protecting group,

M is a protecting group which forms an ester at the carboxyl groups, and is stable during any condensation employed to obtain the compound,

N is a nitrogen containing group which can be treated to form an amine, and which allows a stereospecific linkage during any condensation employed to obtain the compound,

R is selected from the group consisting of:

- a) a permanent protecting group,
- b) an inert protecting group which is stable during removal of the temporary protecting groups, semi-permanent protecting groups and permanent protecting groups, and

R' is a permanent protecting group.

which compound is selected from the group consisting of:

Compounds I, III, V, VI, VII, VIII, IX, X, XI and XII wherein

R1 substituents are not the same, and are selected from the group consisting of

- a) functional groups which are selected from the group consisting of SO_3 groups and PO_3 groups,
- b) permanent protecting groups, which permanent protecting groups are stable and do not migrate to

1

different carbon positions during removal of the semipermanent protecting groups and the introduction of the
functional groups to replace semi-permanent protecting
groups, which permanent protecting groups also are
removable in the presence of the functional groups, are
stable during the condensation, and which allow a
stereospecific linkage during any condensation employed
to obtain the compound, and which permanent protecting
groups are stable during removal of any temporary
protecting group,

M is a protecting group which forms an ester at the carboxyl groups, and is stable during any condensation employed to obtain the compound,

N is a nitrogen containing group which can be treated to form an amine, and which allows a stereospecific linkage during any condensation employed to obtain the compound,

R is selected from the group consisting of:

- a) a permanent protecting group,
- b) an inert protecting group which is stable during removal of the temporary protecting groups, semi-permanent protecting groups and permanent protecting groups, and

R' is a permanent protecting group.

189. A substantially pure compound of a single structure, which compound is selected from the group consisting of:

Compounds I, III, V, VI, VII, VIII, IX, X, XI and XII wherein

 R_1 substituents are not the same, and are selected from the group consisting of

- a) functional groups which are selected from the group consisting of SO_3 groups and PO_3 groups, and
 - b) OH groups,

M is a protecting group which forms an ester at the carboxyl groups, and is stable during any condensation employed to obtain the compound,

N is the same or different and is selected from the group consisting of

- a) an amine,
- b) NH acetyl, and
- c) NH SO_3

R is selected from the group consisting of:

- a) An OH group,
- b) an inert protecting group which is stable during removal of the temporary protecting groups, semi-permanent protecting groups and permanent protecting groups, and R' is OH.

The substantially pure compound of claim 189
wherein N is selected from the group consisting of NH acetyl and
NH SO₃ and wherein M is removed and the compound forms an anion.


The substantially pure compound IX of claim 194 wherein the R₁ substituents are selected from the group consisting of semi-permanent protecting groups and permanent protecting groups, wherein R is a permanent protecting group, wherein R, is a permanent protecting group, and wherein the semi-permanent protecting groups are sp groups and wherein the permanent protecting groups are p groups, which compound has the formula

wherein R₁ substituents are selected from the group consisting of OH groups and permanent protecting groups, wherein R is a permanent protecting group, wherein R' is a permanent protecting group, and wherein the permanent protecting groups are p groups, which compound has the formula

The substantially pure compound IX of claim 188 wherein R₁ substituents are selected from group consisting of SO₃ groups and permanent protecting groups, wherein R is a permanent protecting group, and wherein R' is a permanent protecting group, and wherein the permanent protecting groups are p groups, which compound has the formula

The substantially pure compound IX of claim 189 wherein R_1 substituents are selected from the group consisting of SO_3 groups and OH groups, wherein R is an OH group, R' is an OH group, and N is selected from the group consisting of an amine, NH acetyl, and NH SO_3 which compound has the formula

The substantially pure compound IX of claim 190 wherein sp is SO₃ and p is OH, and N selected from the group consisting of NH acetyl and NH SO₃ and M is removed to form an anion of the compound, which compound has the formula



48 196. 45 or 186

The substantially pure compound of any of claims 194,

wherein

- a) any nitrogen containing group is selected from the group consisting of
 - 1. N₃,
 - 2. NH lower acyl, and
 - 3. NHCO lower arylalkyl;
- b) any protecting group at the carboxyl is selected from the group consisting of
 - 1. lower alkyl, and
 - 2. aryl;
- c) any semi-permanent protecting group is lower acyl;
- d) any temporary protecting group is selected from the group consisting of

- 1. -O-lower acyl,
- 2. -0-allyl,
- -0-propenyl,
- 4. halogenated -O-lower acyl, and
- 5. -O-p-methoxybenzoyl;
- e) any permanent protecting group is benzyl,
- f) any reactive group is selected from the group consisting of
 - 1. halogen,
 - 2. lower imidoyl, and
- 3. an orthoester formed between the carbon 1 and carbon 2 positions where the reactive group occupies a position at carbon 1 of a uronic acid unit,
 - g) any inert protecting group is -O-lower alkyl, and
 - h) any functional group is SO3.

191. The substantially pure compound of claim 196 wherein

- a) any nitrogen containing group is selected from the group consisting of
 - 1. N_3 ,
 - 2. NH acetyl, and
 - 3. NHCO benzyl;
- b) any protecting group which forms an ester at the carboxyl is methyl;
- c) any semi-permanent group is acetyl;

- d) any temporary group is selected from the group consisting of
 - 1. -0-acetyl,
 - 2. -O-benzyl,
 - 3. -0-allyl,
 - 4. -O-propenyl,
 - 5. monochloro-O-acetyl,
 - 6. trichloro-O-acetyl, and
 - 7. -O-p-methoxybenzoyl;
- e) any permanent group is benzyl;
- f) any reactive group is selected from the group consisting of
 - 1. Br,
 - 2. Cl,
 - 3. (an orthoester having between 3 and 6 carbons, and
 - 4. C(NH) CCl₃;
- g) any inert blocking group is an -0-lower alkyl group having between 1 and 4 carbons, and
- h) any functional group is SO3.

A substantially pure heparin chain of a single structure comprised of 2 to 12 saccharide units.

A substantially pure oligosaccharide of a single structure comprised of 2 to 12 alternating D-glucosamine and